Trastuzumab deruxtecan (DS-8201a) is a novel antibody-drug conjugate (ADC) of human epidermal growth factor receptor 2 (HER2) targeted antibody and DNA topoisomerase Ⅰ inhibitor (deruxtecan

DXd). DS-8201a has the characteristics of loading new cytotoxic drugs

high proportion of drug antibodies and high cell membrane permeability. Compared to traditional anti-HER2 drugs only aimed at patients with overexpression of HER2

DS-8201a can also play a role in tumors with high and low expressions of HER2. So far

phase Ⅰ to Ⅲ clinical trials have been carried out in a variety of solid tumors

such as breast cancer

gastric cancer

colorectal cancer and non-small cell lung cancer. Studies have shown results

including indications

toxicity and safety

determination of effective dose

comparison with existing first-line and posterior-line standard chemotherapy regimens

and efficacy comparison between monotherapy and combination therapy. It may provide a new therapeutic method for clinical treatment of tumors with overexpression or low expression of HER2

and pulmonary symptoms should be monitored during use. In this review

the drug structure characteristics

related clinical research progress and prospect of DS-8201a were summarized.